Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study.

Shi LX, Liu XM, Shi YQ, Li QM, Ma JH, Li YB, Du LY, Wang F, Chen LL

Journal of diabetes investigation13 Jun 2019Cited by 13 (Europe PMC)

PMID31102326PMCIDPMC6944837DOI10.1111/jdi.13075PepBankPUB-31102326

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study15

15 results from studies that gave the peptide. 15 results from people.

01HumanRandomized controlled trialEfficacy outcome
In Chinese patients with diabetes, dulaglutide 1.5 mg was non-inferior and superior to glimepiride for HbA1c reduction.
In plain wordsIn Chinese patients with diabetes, dulaglutide 1.5 mg lowered HbA1c more than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change
Study
n = 378
Comparator
Glimepiride
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Measurements
HbA1c difference
−0.53%
versus glimepiride
Source sentences
Summary
The least-squares mean differences (95% confidence interval) versus glimepiride were dulaglutide 1.5 mg, -0.53% (-0.74, -0.32) and dulaglutide 0.75 mg, -0.32% (-0.53, -0.12).
4 context sentences(design, population, supporting numbers)
Summary · context
Dulaglutide 1.5 mg and 0.75 mg were non-inferior (P < 0.001) and superior (P ≤ 0.002) versus glimepiride for the change in glycated hemoglobin from baseline to week 26.
Summary · context
The primary objective of the study was to investigate the non-inferiority of dulaglutide 1.5 mg versus glimepiride by the change from baseline to week 26 in glycated hemoglobin (non-inferiority margin 0.4%).
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232601
02HumanRandomized controlled trialEfficacy outcome
In Chinese patients with diabetes, dulaglutide 0.75 mg was non-inferior and superior to glimepiride for HbA1c reduction.
In plain wordsIn Chinese patients with diabetes, dulaglutide 0.75 mg lowered HbA1c more than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change
Study
n = 383
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 26 weeksAs given in this study (human).
Measurements
HbA1c difference
−0.32%
versus glimepiride
Source sentences
Summary
The least-squares mean differences (95% confidence interval) versus glimepiride were dulaglutide 1.5 mg, -0.53% (-0.74, -0.32) and dulaglutide 0.75 mg, -0.32% (-0.53, -0.12).
3 context sentences(design, population, supporting numbers)
Summary · context
Dulaglutide 1.5 mg and 0.75 mg were non-inferior (P < 0.001) and superior (P ≤ 0.002) versus glimepiride for the change in glycated hemoglobin from baseline to week 26.
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232602
03HumanRandomized controlled trialEfficacy outcome
In Chinese patients with diabetes, dulaglutide 0.75 mg reduced fasting glucose more than glimepiride.
In plain wordsIn Chinese patients with diabetes, dulaglutide 0.75 mg lowered fasting blood sugar more than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting blood glucose
Study
n = 383
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
The decrease from baseline to week 26 in fasting blood glucose was significantly more pronounced in both the dulaglutide groups versus the glimepiride group (P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232605
04HumanRandomized controlled trialSafety outcome
In Chinese patients with diabetes, hypoglycemia incidence was lower with dulaglutide 0.75 mg than glimepiride.
In plain wordsIn Chinese patients with diabetes, low blood sugar affected fewer patients with dulaglutide 0.75 mg than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHypoglycemia incidence
Study
n = 383
Comparator
Glimepiride
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.75 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
The overall incidence and rate of hypoglycemia were lower in both of the dulaglutide groups versus the glimepiride group.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232607
05HumanRandomized controlled trialSafety outcome
In Chinese patients with diabetes, hypoglycemia rates were lower with dulaglutide 0.75 mg than glimepiride.
In plain wordsIn Chinese patients with diabetes, low blood sugar events were less frequent with dulaglutide 0.75 mg than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHypoglycemia event rate
Study
n = 383
Comparator
Glimepiride
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.75 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
The overall incidence and rate of hypoglycemia were lower in both of the dulaglutide groups versus the glimepiride group.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232609
06HumanRandomized controlled trialSafety outcome
In Chinese patients with diabetes, diarrhea was among the most frequent gastrointestinal adverse events related to dulaglutide.
In plain wordsIn Chinese patients with diabetes, diarrhea was a frequent gut-related adverse event with dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDiarrhea
Study
n = 383
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
The most frequent gastrointestinal drug-related adverse events with dulaglutide were diarrhea, abdominal distension, nausea and vomiting.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232612
07HumanRandomized controlled trialSafety outcome
In Chinese patients with diabetes, abdominal distension was among the most frequent gastrointestinal adverse events related to dulaglutide.
In plain wordsIn Chinese patients with diabetes, abdominal swelling was a frequent gut-related adverse event with dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableAbdominal distension
Study
n = 383
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
The most frequent gastrointestinal drug-related adverse events with dulaglutide were diarrhea, abdominal distension, nausea and vomiting.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232613
08HumanRandomized controlled trialSafety outcome
In Chinese patients with diabetes, nausea was among the most frequent gastrointestinal adverse events related to dulaglutide.
In plain wordsIn Chinese patients with diabetes, nausea was a frequent gut-related adverse event with dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableNausea
Study
n = 383
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
The most frequent gastrointestinal drug-related adverse events with dulaglutide were diarrhea, abdominal distension, nausea and vomiting.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232614
09HumanRandomized controlled trialSafety outcome
In Chinese patients with diabetes, vomiting was among the most frequent gastrointestinal adverse events related to dulaglutide.
In plain wordsIn Chinese patients with diabetes, vomiting was a frequent gut-related adverse event with dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableVomiting
Study
n = 383
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
The most frequent gastrointestinal drug-related adverse events with dulaglutide were diarrhea, abdominal distension, nausea and vomiting.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232615
10HumanRandomized controlled trialEfficacy outcome
In Chinese patients with diabetes, more patients reached HbA1c below 7.0% with dulaglutide 1.5 mg than glimepiride.
In plain wordsIn Chinese patients with diabetes, more reached the HbA1c target with dulaglutide 1.5 mg than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c below 7.0%
Study
n = 378
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Measurements
Target attainment
71.7%
dulaglutide
Target attainment
57.5%
glimepiride
Source sentences
Summary
Significantly more patients attained glycated hemoglobin <7.0% at week 26 in the dulaglutide 1.5 mg (71.7%) versus the glimepiride (57.5%; P = 0.005) group.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232603
11HumanRandomized controlled trialEfficacy outcome
In Chinese patients with diabetes, dulaglutide 1.5 mg reduced fasting glucose more than glimepiride.
In plain wordsIn Chinese patients with diabetes, dulaglutide 1.5 mg lowered fasting blood sugar more than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting blood glucose
Study
n = 378
Comparator
Glimepiride
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
The decrease from baseline to week 26 in fasting blood glucose was significantly more pronounced in both the dulaglutide groups versus the glimepiride group (P < 0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232604
12HumanRandomized controlled trialSafety outcome
In Chinese patients with diabetes, hypoglycemia incidence was lower with dulaglutide 1.5 mg than glimepiride.
In plain wordsIn Chinese patients with diabetes, low blood sugar affected fewer patients with dulaglutide 1.5 mg than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHypoglycemia incidence
Study
n = 378
Comparator
Glimepiride
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
The overall incidence and rate of hypoglycemia were lower in both of the dulaglutide groups versus the glimepiride group.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232606
13HumanRandomized controlled trialSafety outcome
In Chinese patients with diabetes, hypoglycemia rates were lower with dulaglutide 1.5 mg than glimepiride.
In plain wordsIn Chinese patients with diabetes, low blood sugar events were less frequent with dulaglutide 1.5 mg than glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHypoglycemia event rate
Study
n = 378
Comparator
Glimepiride
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
The overall incidence and rate of hypoglycemia were lower in both of the dulaglutide groups versus the glimepiride group.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232608
14HumanRandomized controlled trialEfficacy outcome
In Chinese patients with diabetes, body weight decreased from baseline with dulaglutide 0.75 mg and increased with glimepiride.
In plain wordsIn Chinese patients with diabetes, body weight fell from baseline with dulaglutide 0.75 mg but rose with glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight change
Study
n = 194
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
0.75 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
At week 26, bodyweight had increased from baseline in the glimepiride group and decreased from baseline in both dulaglutide groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232611
15HumanRandomized controlled trialEfficacy outcome
In Chinese patients with diabetes, body weight decreased from baseline with dulaglutide 1.5 mg and increased with glimepiride.
In plain wordsIn Chinese patients with diabetes, body weight fell from baseline with dulaglutide 1.5 mg but rose with glimepiride.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight change
Study
n = 189
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg once weekly · 26 weeksAs given in this study (human).
Source sentences
Summary
At week 26, bodyweight had increased from baseline in the glimepiride group and decreased from baseline in both dulaglutide groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a post-hoc analysis of a Chinese randomized, double-blind, non-inferiority, phase III study.
Summary · context
Patients (n = 572) with inadequate glycemic control received dulaglutide 1.5 mg (n = 189) or 0.75 mg (n = 194) once-weekly or glimepiride (1-3 mg/day; n = 189) for 26 weeks.
Report a problemFND-3110232610

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Efficacy and safety of dulaglutide monotherapy compared with glimepiride in Chinese patients with type 2 diabetes: Post-hoc analyses of a randomized, double-blind, phase III study.

Summary

Results from this study15

Version history

Subjects

Publication types

MeSH terms

Keywords